Place: Newsroom / Client Work / Detail
GLO advises Connect Biopharma (Nasdaq: CNTB) on its initial public offering and listing on NASDAQ

Connect Biopharma Holdings Limited (“Connect Biopharma”) (Nasdaq: CNTB) announced the pricing of its initial public offering of 11,250,000 American Depositary Shares (“ADSs”), representing 11,250,000 ordinary shares of Connect Biopharma, at a public offering price of US$17.00 per ADS on March 19, 2021.


The number of ADSs issued at closing included the exercise in full of the underwriters’ option to purchase 1,687,500 additional ADSs from Connect Biopharma at the initial public offering price, less underwriting discounts and commissions. The gross proceeds from the offering were approximately US$219.9 million, before deducting underwriting discounts and commissions and other offering expenses payable by Connect Biopharma. Each ADS represents one ordinary share of Connect Biopharma. The ADSs began trading on the Nasdaq Global Market on March 19, 2021 under the ticker symbol "CNTB”.


Connect Biopharma is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T-cell-driven research,


Jefferies LLC, SVB Leerink LLC, Piper Sandler & Co. and China International Capital Corporation Hong Kong Securities Limited acted as joint book-running managers for the offering. Global Law Office acted as the PRC counsel to the joint book-running managers, providing a full range of legal services. Our team was led by our Shenzhen-based partner Carrie Sun, and the team members include Danwei Wen, Rongrong Zheng and Youcheng Bi as well.